Fulgent Genetics Raises Guidance After Strong Jump in Q1 Core Revenues
As a result of the strong core growth, the company raised its full-year revenue guidance to $250 million from previous guidance of $240 million.
Fulgent Genetics Q4 Revenues Fall 73 Percent, Beat Expectations
The firm said its non-COVID core revenues nearly doubled for the quarter as well as for full-year 2022.
Fulgent Q3 Total Revenues Fall 54 Percent, Non-COVID Revenues Double
Separately, Fulgent Genetics also announced that it will acquire Fulgent Pharma for $100 million.
360Dx Top 30 Tumbles in August
Of the 30 diagnostic companies in the index, 22 saw their share prices decline, while eight firms saw stock prices rise.
Fulgent Genetics Q2 Revenues Fall 18 Percent on Declining COVID Business
The firm touted a doubling of its core non-COVID business despite challenging macroeconomic headwinds.
Apr 21, 2022
Jan 4, 2022
360Dx Index Rises 20 Percent in 2021
Aug 10, 2021
Mar 4, 2021